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The strongest genetic influence on immune control in HIV-1 infection is the HLA class I genotype. Rapid disease progression in
B-clade infection has been linked to HLA-B*35 expression, in particular to the less commonHLA-B*3502 and HLA-B*3503 sub-
types but also to the most prevalent subtype, HLA-B*3501. In these studies we first demonstrated that whereas HLA-B*3501 is
associated with a high viral set point in two further B-clade-infected cohorts, in Japan andMexico, this association does not hold
in two large C-clade-infected African cohorts. We tested the hypothesis that clade-specific differences in HLA associations with
disease outcomes may be related to distinct targeting of critical CD8 T-cell epitopes. We observed that only one epitope was
significantly targeted differentially, namely, the Gag-specific epitope NPPIPVGDIY (NY10, Gag positions 253 to 262) (P 2
105). In common with two other HLA-B*3501-restricted epitopes, in Gag and Nef, that were not targeted differentially, a re-
sponse toward NY10 was associated with a significantly lower viral set point. Nonimmunogenicity of NY10 in B-clade-infected
subjects derives from the Gag-D260E polymorphism present in90% of B-clade sequences, which critically reduces recognition
of the Gag NY10 epitope. These data suggest that in spite of any inherent HLA-linked T-cell receptor repertoire differences that
may exist, maximizing the breadth of the Gag-specific CD8 T-cell response, by the addition of even a single epitope, may be of
overriding importance in achieving immune control of HIV infection. This distinction is of direct relevance to development of
vaccines designed to optimize the anti-HIV CD8 T-cell response in all individuals, irrespective of HLA type.
Several genome-wide association studies now indicate that thehost HLA class I genotype is the major genetic determinant of
HIV-1 disease progression (19, 20, 61). Previously it had been
established that differences in HLA allele expression have a sub-
stantial impact on HIV disease outcome, in both B-clade (10, 19,
20, 59) and C-clade (38, 44, 54, 63) infection. Variation at the
HLA-B locus has the greatest impact on viral set point (20, 38).
This may result from the increased diversity of HLA-B compared
to non-HLA-B alleles (28), affecting the repertoire, protein spec-
ificity, and peptide-binding characteristics of epitopes presented
byHLA-B alleles (38, 39, 41). In addition,HLA-Bw4 alleles can act
as KIR ligands and modulate an NK response, with certain HLA-
KIR combinations resulting in selection pressure on HIV and/or
significantly influencing viral set point (2, 3, 52, 68).
The mechanisms by which certain HLA alleles are consistently
linked with particular HIV disease outcomes remain unresolved.
Several possible mechanisms have been proposed. First, HLA-as-
sociated immune control has been linked to the specificity of the
CD8 T-cell response (39, 54). In this way, HLA alleles such as
HLA-B*57 or HLA-B*27, associated with immune control (4, 46,
59), restrict dominant Gag-specific responses, escape from which
results in a substantial reduction in viral replicative capacity (13,
15, 46, 53, 65). In contrast, HLA alleles such as HLA-B*35, asso-
ciated with rapid disease progression (12), restrict dominant
epitopes inNef, Env, and other non-Gag proteins (7, 39, 58, 67, 69,
72, 73).
A secondmechanismproposed for the association of particular
HLA types with characteristicHIV disease outcomes is through an
impact on antiviral NK activity, since certain HLA alleles have the
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potential to act as KIR ligands. The HLA alleles associated with
lowest viral set point tend to be HLA-Bw4 alleles (22). HLA-Bw4
alleles expressing Ile at HLA residue 80 significantly reduce the
viral set point in combination with either KIR3DS1 or KIR3DL1
(51, 52). However, the impact of HLA-KIR combinations only
partially explains the effect of protective alleles such as HLA-B*27
and HLA-B*57 or of disease susceptibility alleles such as HLA-
B*35 (5, 52).
A thirdmechanism,more recently proposed (41), suggests that
disease susceptibility (61) HLA alleles such as HLA-B*0702 and
HLA-B*3501 have peptide-binding motifs such that large num-
bers of self peptides can bind, and hence a relatively large propor-
tion of the T-cell receptor (TcR) repertoire would be lost through
negative selection of autoreactive T cells in the thymus. In con-
trast, protective alleles such as HLA-B*2705 and HLA-B*5701
have more restrictive peptide-binding motifs, with a requirement
for Arg at P2 in the case of HLA-B*2705 and a strong preference
for Trp at theC-terminal position in the case ofHLA-B*5701 (50).
This would result in fewer autoreactive T cells being deleted in the
thymus via negative selection and therefore a relatively large TcR
repertoire remaining to accommodate the challenge of epitope
variation inevitably presented by viruses such as HIV.
An additional mechanism proposed to explain the status of
HLA-B*3503 as linked with more rapid disease progression than
HLA-B*3501 (25), from which it differs by only one amino acid,
derives from the observation that HLA-B*3503 binds with signif-
icantly greater affinity thanHLA-B*3501 to immunoglobulin-like
transcript 4 (ILT-4), an inhibitory major histocompatibility com-
plex (MHC) class I receptor expressed on dendritic cells (34).
These data suggest the possibility that dendritic cell function may
be significantly affected by a variety of HLA molecules, thereby
explaining a range of differential HLA associations with HIV dis-
ease outcome.
We here describe an observation that allows us to test the first
of these hypothetical mechanisms. While HLA-B*3501 is associ-
ated with less rapid progression to HIV disease than the less com-
mon subtypes of HLA-B*35 in Caucasians, B*3502 and B*3503
(25), HLA-B*3501 itself has also been associated with higher-
than-average viremia in B-clade HIV-1 infection (42). For exam-
ple, in a recent study of 3,622 B-clade-infected study subjects,
HLA-B*3501 was strongly associated with HIV disease progres-
sion (61). However, in a cohort of C-clade-infected study subjects
(n 1,210) in Durban, South Africa, we noted that HLA-B*3501
is somewhat protective: viral set points tend to be somewhat lower
in HLA-B*3501-positive subjects. Indeed, having removed the ef-
fect of HLA-B*57, HLA-B*5801, HLA-B*1801, and HLA-B*5802,
the alleles having the strongest impact on viral set point and ab-
solute CD4 count (38), HLA-B*3501 was the HLA-B allele associ-
atedwith the highest absolute CD4 counts (44, 54) in this C-clade-
infected cohort.
We show here, first, that this observation of clade specificity of
theHLA-B*3501 effect on viral set point could be replicated in two
additional B-clade-infected cohorts, namely, in Japan and inMex-
ico, and in an additional C-clade-infected cohort in Botswana.We
then tested the hypothesis that the clade-specific difference in
HLA-B*3501-associated HIV disease outcome could be related to
altered specificity of the CD8 T-cell response. Based on the “Gag
hypothesis” as described above,HLA-B*3501-restricted responses
in C-clade infection would tend to be more Gag directed and less
Nef/Env directed than in B-clade infection.
MATERIALS AND METHODS
Ethics statement. Ethics approval was given by the following: the Univer-
sity of KwaZulu-Natal Review Board and theMassachusetts General Hos-
pital Review Board (Durban cohort); the Office of Human Research Ad-
ministration, Harvard School of Public Health, and the Health Research
Development Committee, Botswana Ministry of Health (Gaborone co-
hort); the Oxford Research Ethics Committee (Thames Valley and other
cohorts); and the Ethics Committees of Kumamoto University and Na-
tional Centre for GlobalHealth andMedicine (Kumamoto cohort). Study
subjects from all cohorts gave written informed consent for their partici-
pation.
Study cohorts. We studied a total of 3,132 adults with chronic, anti-
retroviral therapy (ART)-naïve HIV-1 infection, recruited from six
cohorts as follows: (i) Durban, South Africa (C clade; n  1,218), as
previously described (38, 39, 46, 54); (ii) Gaborone, Botswana (C clade;
n  514) via the Mma Bana study, as previously described (66); (iii)
Kumamoto, Japan (B clade; n  242), as previously described (37); and
(iv) Mexico City, Mexico (B clade; n 771), as previously described (6)
(see Table S1 in the supplementalmaterial); (v) the ThamesValley cohort,
United Kingdom (mixed clades; n  237), as previously described (60,
62); and (vi) a B-clade-infected cohort of 150 subjects drawn from mul-
tiple ethnicities, also as previously described (24). Viral loads were deter-
mined using Roche Amplicor version 1.5 assay; CD4 T-cell counts were
determined by flow cytometry.
HLA typing and classification. HLA typing from genomic DNA was
undertaken by sequence-based typing as previously described (38). Lo-
cus-specific PCRproducts of exons 2 and 3were amplified and sequenced.
In the Kumamoto cohort, 32/37 subjects with HLA-B*35 were typed to 4
digits, and all 32 of these were HLA-B*3501 positive; because of this, and
because of a previous analysis of 1,018 Japanese subjects (36) which
showed that 158/159 subjects with HLA-B*35 had HLA-B*3501, the re-
maining 5 Japanese subjects were designated HLA-B*3501 positive. Like-
wise, in the southern African cohorts, 96/102HLA-B*35-positive subjects
typed to 4 digits were HLA-B*3501 positive. For 23 Durban subjects in
whom HLA-B*35 typing had been undertaken only to 2-digit resolution,
we used an HLA completion tool (http://atom.research.microsoft.com
/HLACompletion) (47) to predict themost likely 4-digit HLA-B*35 allele.
In all cases HLA-B*3501 was predicted as the 4-digit type with a high level
of statistical certainty (probability of B*3501, 0.86 to 0.98; median, 0.97).
For this reason, we designated all 23 Durban subjects with HLA-B*35
typed to 2-digit resolution as HLA-B*3501.
Definition of HLA-B*3501-restricted epitopes. To define a compre-
hensive list of HLA-B*3501-restricted epitopes, we identified previously
characterized epitopes from studies of predominantly B-clade-infected
subjects (Los Alamos “A list”; www.lanl.gov) (48) and also identified five
novel HLA-B*3501-restricted epitopes by testing recognition of 410 over-
lapping 18-mer peptides in a cohort of C-clade-infected subjects (see Ta-
ble S2 in the supplemental material). One of these (HA9) has, since the
start of this study, now been confirmed by another group (74). From this
dual approach, 13 HLA-B*3501-restricted epitopes were identified for
further analysis (Table 1).
IFN- ELISpot assays. Gamma interferon (IFN-) enzyme-linked
immunosorbent spot (ELISpot) assays were undertaken using fresh or
cryopreserved peripheral blood mononuclear cells (PBMCs). We
screened for HIV-1-specific responses statistically associated (q  0.05)
with the expression of HLA-B*3501 by testing a total of 1,010 chronically
infected subjects (n 795 from Durban; n 215 from the Thames Val-
ley) against a panel of 410 overlapping peptides (OLPs) spanning the
entire HIV proteome, as previously described (38, 39, 54). Significant
associations were determined using Fisher’s exact test and corrected for
multiple comparisons using a q value (false-detection rate [FDR]) ap-
proach as previously described (11, 40, 54).
In order to screen subjects with HLA-B*3501 for specific responses to
HLA-B*3501 epitopes, B-clade-infected subjects were tested for IFN-
responses to optimal peptides (Japan, n  30) or against overlapping
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peptides in a previously described B-clade cohort (23, 24) (n  44). C-
clade-infected subjects (n 42) were tested for responses to the C-clade
version of the same epitopes using the respective 18-mer peptides con-
taining the HLA-B*3501 epitopes.
Viruses from all study subjects in the Japan cohort were sequenced to
confirm clade of infection, and only those subjects who were B-clade
infected were included in the study (one subject who was A-clade infected
was excluded). Likewise C-clade infection was confirmed in99% of the
southernAfrican study subjects. The B-clade-infected subjects were tested
for recognition of the version of the peptides corresponding to the B-clade
consensus sequence in Japan, and the C-clade-infected subjects were
tested for recognition of the version corresponding to the C-clade con-
sensus sequence (the 2006 Durban and other Southern African consensus
sequence). Using previously established criteria (38, 39), a response of 100
spot-forming cells (SFC)/106 PBMCwas defined as significantly above the
background response in control wells.
Epitope finemapping andHLA class I tetramer assay.Weconfirmed
HA9 (HPVHAGPIA; Gag positions 216 to 224) as an HLA-B*3501-re-
stricted optimal epitope via assays of PBMCs in subject R051 (HLA-
A*0101, -A*3002, -B*1801, -B*3501, -Cw*0401, -Cw*0501) against the
optimal peptide and four truncations (1 amino acid at the C and N
termini); this experiment was performed in triplicate. Likewise, NY10
(NPPIPVGDIY; Gag positions 253 to 262) was optimized against the PY9
(PPIPVGDIY; Gag positions 254 to 262) using responder PBMCs from
subject H033 (HLA-A*3601, -A*7401, -B*3501, -B*5301, -Cw*0401,
-Cw*0401) in an IFN- ELISpot peptide titration assay.
The corresponding peptide responses were validated usingHLA class I
tetramers and controlled by a mismatched HLA-B*4201 tetramer. A
pretitrated concentration of phycoerythrin (PE)-conjugated tetramers
(43) was used to stain PBMCs, which were incubated for 30 min and
stained with pretitrated extracellular antibodies CD8-Pacific Blue (BD
Pharmingen) and CD3-Pacific Orange (Invitrogen). Dead cells were ex-
cluded using the Vivid LIVE/DEAD marker (Invitrogen). For NY10-Gag
dual-tetramer staining, PBMCs from subject OX030 were stained ex vivo
or in vitro expanded for 12 days using 10 g/ml of NY10-260D or NY10-
260E in culture medium RPMI 1640 (Gibco) supplemented with 10%
human serum, 1% penicillin-streptomycin (Invitrogen), and 10% T-cell
growth factor (Helvetica), costained with HLA-B*3501-NPPIPVGDIY
(PE conjugated) and HLA-B*3501-NPPIPVGEIY (allophycocyanin
[APC] conjugated) pretitrated tetramers (ex vivo PBMCs) or in 2-fold
titrations (cytotoxic T lymphocytes [CTLs]), and subsequently stained
with extracellular antibodies as described above.
Intracellular cytokine staining. PBMCs from subject KI-705 were
stimulated with NY10-260D (NPPIPVGDIY) or NY10-260E (NPPIPGV
EIY) (1M) in culturemedium (RPMI 1640medium supplementedwith
10% fetal calf serum [FCS] and 200 U/ml recombinant human interleu-
kin-2 [IL-2]). After 14 days in culture, the cells were assessed for IFN-
production. Briefly, bulk cultures were cocultured with C1R cells express-
TABLE 1 Thirteen HLA-B*3501-restricted epitopes in HIV-1 from Gag, Pol, Rev, Env, and Nef proteinsa
Protein Clade
Epitope sequenceb
HXB2 position Epitope designation
P2 C terminus
2 2
p24 Gag B HPVHAGPI A Gag 216-224 Gag HA9*
C -------- -
B NPPIPVGEI Y Gag 253-262 Gag NY10
C -------D- -
RT B TVLDVGDA Y Pol 262-270 RT TY9
C -------- -
B VPLDKDFRK Y Pol 273-282 RT VY10
C ----E--- -
B NPDIVIYQ Y Pol 330-338 RT NY9
C --E----- -
B EPIVGAETF Y Pol 587-596 RT EY10*
C ---A----- -
Int B IPAETGQETAY Pol 804-814 Int IY11*
C -----------
Rev B KTVRLIKFL Y Rev 14-23 Rev KY10, Rev QY10*
C QA--I--I- -
gp120 B VPVWKEATTTL Env 42-52 Env VL11
C -----K-- -
B DPNPQEVV L Env 78-86 Env DL9
C ------M- -
gp41 B TAVPWNAS W Env 606-614 Env TW9
C ------S- -
Nef B VPLRPMT Y Nef 73-81 Nef VY8, Nef VF8
C ------- F
B YPLTFGWC Y Nef 135-143 Nef YY9, Nef YF9*
C -------- F
a The 13 epitopes include 8 from the Los Alamos database “A list” (www.lanl.gov) and 5 new HLA-B*3501-restricted optimal epitopes (indicated by asterisks).
b The B- and C-clade consensus sequences of each epitope are listed; a dash indicates no difference between clades. Residues at position 2 and at the C terminus are in bold.
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ingHLA-B*3501 pulsedwithNY10-260E orNY10-260Dpeptide for 2 h at
37°C. Brefeldin A (10 g/ml) was then added, and the cocultures were
continued for additional 4 h. Cells were stained with phycoerythrin (PE)-
labeled anti-CD8 monoclonal antibody (Dako Corporation, Glostrup,
Denmark) and subsequently fixed (4% paraformaldehyde), permeabil-
ized (0.1% saponin and 20% NCS in phosphate-buffered saline), and
intracellularly stained with fluorescein isothiocyanate (FITC)-labeled
anti-IFN-monoclonal antibody (MAb) (PharMingen, San Diego, CA).
Samples were acquired on a FACSCalibur instrumentwithin 24 h of stain-
ing and data analyzed using FlowJo version 8.8.6.
Generation of mutant virus NL43-2 E260D and epitope processing
assay. The NL43-2-Gag260D mutant virus was generated by introducing
the Gag260D mutation into the NL43-2 Gag260E backbone using site-
directed mutagenesis (Invitrogen). After virus generation, 721.221-CD4-
B*3501 and 721.221 target cells were infected with NL43-2 B-clade
WT(Gag260E) or NL4-32-Gag260D mutant virus. The infection rates
were determined by the level of intracellular p24-positive cells stained
with FITC-conjugated anti-p24 MAb (KC57-FITC; BD Biosciences) and
followed over 6 days. When the level of p24-positive target cells reached
80%, the Gag NY10-specific CD8 T-cell line and the control Pol-EY10
CD8 T-cell clone was cocultured with the target cells for 5 h in the
presence of brefeldin A and subsequently stained for intracellular IFN-
as described above. The level of IFN--positive CD8 T cells after cocul-
ture was used as ameasure of the level of specific epitope presentation and
controlled by uninfected HLA-matched and infected HLA-negative
721.221 cells. Peptide-pulsed HLA-matched target cells were used as pos-
itive controls for optimal epitope presentation. Samples were acquired on
a FACSCalibur instrumentwithin 24 h of staining and data analyzed using
FlowJo version 8.8.6
Peptide-MHC binding studies. HLA-peptide binding studies were
undertaken using a luminescent oxygen channeling immunoassay
(LOCI) as previously described (29). We tested binding for 12 HLA-
B*3501 epitopes as shown in Table S3 in the supplemental material. Bind-
ing assays were performed in quadruplicate; the reported result is the
mean of the four values obtained.
Stability of binding (binding half-life) was determined as described
previously (30). Briefly, biotinylated HLA-I heavy chain, 125I-labeled
beta-2-microglobulin (B2m), and peptide were allowed to fold into pep-
tide–HLA-I complexes in streptavidin-coated scintillation microplates
(Flashplate Plus; Perkin-Elmer, Boston, MA) for 24 h at 18°C. Excess
unlabeled B2m was added, and dissociation was initiated by placing the
microplate in a scintillation reader (TopCount NXT; Perkin-Elmer, Bos-
ton, MA) operating at 37°C. The scintillation signal was monitored by
continuous reading of the microplate for 24 h. Half-lives were calculated
from dissociation curves using the exponential decay equation in Prism
v.5.0a (GraphPad, San Diego, CA). Assays were performed in duplicate;
the mean value from two experiments is reported.
Statistical analysis. Statistical analysis was undertaken using Graph-
Pad Prism v.5.0a (GraphPad, San Diego, CA). To define the sites of new
putative HLA-B*3501 epitopes, relationships between HIV-1 sequence
polymorphisms and HLA class I expression and between ELISpot re-
sponses and HLA class I expression were determined using Fisher’s exact
test (corrected for viral lineage in the case of sequence analysis) and cor-
rected for multiple comparisons using a q value (false-detection rate), as
previously described (11, 54).
RESULTS
Consistent differential HLA-B*3501-association with viral set
point in B- and C-clade infection. We first sought to test the
consistency of our initial observation that, in contrast to its impact
in B-clade infection (7, 21, 59),HLA-B*3501 is not associatedwith
high viral set point in C-clade infection (38, 44). In B-clade-in-
fected cohorts in Mexico and in Japan, HLA-B*3501 is associated
with a high viral set point (P 0.06 and P 0.0005, respectively)
(Fig. 1 and 2). In contrast, in a C-clade-infected Botswanan co-
hort, HLA-B*3501 is somewhat protective, although this did not
reach statistical significance (Fig. 1 and 2).
HLA-B*3501 is also associated with higher absolute CD4 T-
cell counts in subjects with C-clade infection (Durban, P 0.06;
FIG 1 Ranking of HLA-B alleles with respect tomedian viral load (VL) in chronic HIV-1 infection in B- andC-clade-infected study cohorts. Boxes showmedian
and 25th and 75th centiles; whiskers show 10 to 90% confidence intervals. HLA-B*3501 is highlighted in gray. Dashed lines indicate median VL for the whole
cohort. P values by Mann-Whitney test, comparing VL for subjects with each allele to the whole population: ***, P 0.0001; **, P 0.001. Alleles represented
are those occurring at0.5% phenotypic frequency and for which a minimum of 5 subjects had VL data available. (A) Kumamoto, Japan (median VL, 19,500
RNA copies/ml). (B) Gaborone, Botswana (median VL, 19,150 RNA copies/ml). For equivalent data for Durban, South Africa, see reference 55.
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Gaborone, P  0.16; P  0.01 when data were pooled; median
absolute CD4 counts, 439 versus 369 cells/mm3 in HLA-B*3501-
positive versus HLA-B*3501-negative subjects) (data not shown).
In contrast, HLA-B*3501 is associated with lower absolute CD4
counts in subjects with B-clade infection (Mexico, P  0.01; Ja-
pan, P  0.3; P  0.01 when data were pooled; median absolute
CD4 counts, 249 versus 370 cells/mm3 in HLA-B*3501-positive
versus HLA-B*3501-negative subjects) (data not shown).
Thus, in two large C-clade-infected cohorts, HLA-B*3501 is
associatedwith lower viral loads and higherCD4T-cell counts in
chronic HIV infection, whereas in B-clade-infected cohorts, such
as those studied in Japan and inMexico, HLA-B*3501 tends to be
associated with a higher viral set point and lower absolute CD4
count.
HLA-B*3501-restricted CD8 T-cell responses in B- and C-
clade infection. In order to investigate whether the observed
difference in HLA-B*3501-associated HIV disease outcome in B-
and C-clade-infected cohorts is related to clade-specific differ-
ences in the CD8T-cell activity, wemeasured responses inHLA-
B*3501-positive subjects infected with B- or C-clade virus to a
comprehensive panel of HLA-B*3501-restricted epitopes (Table
1). This panel comprised epitopes previously defined from studies
of B-clade-infected subjects with HLA-B*3501 and published in
the Los Alamos Immunology database “A list” (www.hiv.lanl.gov)
(48), togetherwith 5 additional novel epitopes that were identified
by analysis of CD8 T-cell responses in a cohort of 1,010 study
subjects (40) to a panel of 410 overlapping 18-mer peptides
(OLPs) spanning the C-clade proteome (see Table S2 in the
supplemental material). An illustration of the approach that
was used to identify these HLA-B*3501-restricted epitopes is
shown for HPVHAGPIA (Gag positions 216 to 224) (HA9) (see
Fig. S1 in the supplemental material), which was recently also
described by another group (74) as a p24Gag epitope restricted by
HLA-B*3501.
For all the epitopes identified that were not listed in the Los
Alamos Immunology database (www.hiv.lanl.gov) (48), in each
case strong binding avidities to HLA-B*3501 (with the Kd [disso-
ciation constant] ranging between 1 and 55 nM) were demon-
strated (data not shown), and a CD8 T-cell response to each was
detected in2 study subjects tested (see below). In the process of
validating the novel and previously published HLA-B*3501-re-
stricted epitopes using HLA-class I tetramers (40), we noted one
epitope that had been previously identified via an epitope predic-
tion approach as PPIPVGDIY (PY9) (Gag positions 254 to 262)
(64).We demonstrated that the true optimal epitope is the 10-mer
NPPIPVGDIY (NY10) (Gag positions 253 to 262), which is con-
sistently recognized at1/1,000 of the concentration of PY9 (Fig.
3A). HLA-B*3501 tetramer staining of antigen-specific cells was
readily observed using the 10-mer NY10 (Fig. 3B) but was never
achieved using the 9-mer PY9. This process of distinguishing the
correct epitope, NY10, from the incorrect epitope, PY9, was of
crucial significance in understanding the differential impact of
HLA-B*3501 in B- and C-clade HIV infection (see below).
FIG 2 Median viral load in subjects with and without HLA-B*3501 in B- and
C-clade-infected study cohorts. Boxes show median and 25th and 75th cen-
tiles; whiskers show 10 to 90% confidence intervals. (A) Kumamoto, Japan (B
clade); (B)Mexico City, Mexico (B clade); (C) Gaborone, Botswana (C clade);
(D) Durban, South Africa (C clade). P values are by the Mann-Whitney test.
FIG 3 Optimization of the NY10 Gag epitope (NPPIPVGDIY). (A) IFN- ELISpot responses to titrated amounts of the 9-mer PPIPVGDIY versus the 10-mer
NPPIPVGDIY peptides made by an HLA-B*3501-positive adult subject with chronic B-clade HIV-1 infection (Thames Valley subject H033, HLA-A*3601,
-A*7401, -B*3501, -B*5301, -Cw*0401, -Cw*0401). (B) Unequivocal definition of the correct HLA-B*3501-restricted optimal epitope NY10 using an HLA-
B*3501–NY10 tetramer to stain the NY10 responder PBMCs from the same subject (H033) as used for panel A. Results from one representative of two
independent experiments are shown.
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Gag NY10 is the single epitope differentially targeted by
HLA-B*3501 subjects with B- and C-clade infection. Reactivity
to the panel of HLA-B*3501-restricted epitopes defined was de-
termined in HLA-B*3501-positive subjects with B-clade infection
(n  74) and in subjects with C-clade infection (n  42) using
ELISpot assays (Fig. 4). Overall, p24 Gag-specific epitopes were
targeted significantly more frequently by the C-clade-infected
B*3501-positive study subjects (55% versus 31%; P  0.02 by
Fisher’s exact test), whereas Env-specific epitopes were targeted
more frequently by B-clade-infected B*3501-positive study
subjects (10% versus 26%; P 0.05 by Fisher’s exact test) (Fig.
4A). At the individual epitope level, the single statistically sig-
nificant clade-specific difference was in the response to the Gag
NY10 epitope (Gag positions 253 to 262; P  2 	 10
5). A
response to this epitope was seen in only 5% of B-clade-in-
fected subjects, versus 38% of C-clade-infected subjects. Al-
though the Rev epitope KY10 (Rev positions 14 to 23) was also
predominantly targeted in C-clade infection, this difference in
recognition in B- and C clade-infected HLA-B*3501-positive
subjects did not reach statistical significance after correction
for multiple comparisons.
Both p24 Gag responses and one Nef response are consis-
tently associated with lower viral load in subjects with HLA-
B*3501. Having determined which HLA-B*3501-restricted
epitopes are targeted in B- and C-clade-infected subjects with
HLA-B*3501, we next investigated which of these responses ap-
pear to be most effective in bringing about a low viral set point.
Two responses were consistent in being associated with a lower set
point in the responders compared to the nonresponders in both
B- and C-clade cohorts, Gag HA9 and Nef VY8 (Fig. 4D). These
two epitopes are targeted equally well in B- and C-clade infection,
and therefore these responses do not help to explain why HLA-
B*3501 is associated with lower viral set points in C-clade infec-
tion. In the case of Gag NY10, however, in B-clade infection there
was only 1 responder among 31 B-clade subjects for whom viral
loads were available. However, in the C-clade-infected cohort, a
response toward Gag NY10 was also associated with a lowered
viremia (P  0.03 by Mann-Whitney test) (Fig. 4D), Thus, the
only HLA-B*3501-restricted response associated with a lower vi-
ral set point for which there was a significant difference in epitope
targeting comparing the B- andC-clade cohortswas theGagNY10
response.
FIG 4 Percentage of HLA-B*3501-positive subjects making IFN- ELISpot responses to 13 HLA-B*3501-restricted epitopes in B- and C-clade infection and the
impact on viral load to HA9 Gag, NY10 Gag and VY/VF8 Nef responses controlled by HLA-B*3501 matched nonresponding individuals. (A) Responses
expressed as protein specific were obtained by pooling the percentage of adult HLA-B*3501-positive subjects with B-clade infection (Kumamoto, Japan)making
IFN- ELISpot responses to individual HLA-B*3501-restricted optimal peptides (n 30 subjects) pooled with another B-clade cohort (23, 44) screened against
18-mer overlapping peptides containing the optimal epitopes (n 44 subjects) (blue) (total of 74 B-clade-infected subjects) and compared to adult subjects with
C-clade infection (southern African subjects) tested against C-clade consensus overlapping peptides containing the corresponding optimal peptides (n  42
subjects) (red). (B) Responses as in panel A but shown for individual epitopes within Gag and Pol proteins. (C) Responses as in panel A but shown for individual
epitopes within Rev, Env, and Nef proteins. (D) Comparison of viral load between responders and nonresponders for B-clade-infected Japanese subjects (n
30), based on responses to optimal peptides, HA9 Gag (left), NY10 Gag (middle), and VY/VF8-Nef (right) (top panels) and C-clade southern African subjects
based on responses toOLPs containing the corresponding optimal peptides (bottompanels). In each case, a positive ELISpot response is defined as100 SFC/106
PBMCs; P values are by Fisher’s exact test (A, B, and C) (and for B and C are shown only when significant after correction for multiple comparisons) or by
Mann-Whitney U test (D).
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Lack of immunogenicity of NY10-260E indicated by strong
selection of the Gag-D260E polymorphism in B- and C-clade
infection and lack of NY10-260E-specific CD8 T-cell re-
sponses.We next addressed the question of why the B-clade ver-
sion of Gag NY10, which differs from the C-clade version only at
position 8 in the epitope, in the replacement of Asp by Glu (Gag-
D260E), appears to be nonimmunogenic, whereas the C-clade
version is highly immunogenic. Although 38% of HLA-B*3501-
positive subjects with chronic C-clade infection show detectable
responses to NY10-260D, analysis of gag sequences in the cohort
indicates that exactly twice that figure, 76%, of HLA-B*3501-pos-
itive subjects carry the Gag-D260Emutation, compared to 28%of
the HLA-B*3501-negative study subjects (Fig. 5A) (P  9 	
10
11). We confirmed that, in every case tested, the NY10-D260E
variant is substantially less well recognized than the C-clade wild-
type NY10-260D (Fig. 5B) and that NY10-D260E is therefore an
escape mutant. Strikingly, NY10-260E is also selected in HLA-
B*3501-positive subjects with B-clade infection (Fig. 5A), in spite
of the fact that close to 90% of B-clade sequences carry Gag-260E
(37). These data suggest that NY10-260E is nonimmunogenic and
that only the small fraction of B-clade-infectedHLA-B*3501-pos-
itive subjects presented with virus expressing the Gag-260D vari-
FIG 5 Selection of Gag-D260E substitution in C-clade infection and effect of this polymorphism on CD8 T-cell recognition and lack of NY10-260E specific
CD8 T cells. (A) Selection of Gag-D260E polymorphism in subjects with HLA-B*3501 from an extended B-clade data set as previously published (24) (n 
1,077; total subjects with HLA-B*3501, n  135 [12.5%]) (left) and selection of Gag-D260E polymorphism in subjects with HLA-B*3501 from an extended
southern African data set (Durban, n 695; Botswana, n 298; Thames Valley Africans, n 59; total subjects with HLA-B*3501, n 45 [4.3%]) (right). (B)
IFN- ex vivo ELISpot responses made by an HLA-B*3501-positive Japanese subject with chronic B-clade infection (subject KI705, HLA-A*2402, -A*2601,
-B*3501, -B*5201, -Cw*0303, -Cw*1202) to optimal epitope NY10 (NPPIPVGDIY) and an escape variant containing the D260E substitution (NPPIPVGEIY)
and IFN- intracellular cytokine staining of CD8 T cells in vitro expanded and tested against titrated amounts of NY10-260E and NY10-260D peptides. One
experiments was performed. (C) IFN- ex vivo ELISpot responses made by an HLA-B*3501-positive subject with chronic B-clade infection (subject OX035,
HLA-A*0201, -A*1101, -B*1801, -B*3501, -Cw*0401, -Cw*0501) to optimal epitope NY10-260D and an escape variant containing the D260E substitution
NY10-260E and dualNY10-260E andNY10-260DHLA-B*3501 tetramer staining of ex vivoPBMCs controlled byHLA-B*4201mismatch tetramer. Results from
one representative of two independent experiments are shown. (D) In vitro-expanded PBMCs from subject OX035 using NY10-260D (top) and NY10-260E
(bottom) peptides and stainedwith titrated amounts of dualHLA-B*3501 tetramers (260D/260E) gated onCD8T cells (dot plots) and expressed asCD3/Tet
positive cells for all tetramer titrations (right) controlled byHLA-B*4201mismatch tetramers.P values are by Fisher’s exact test.One experimentswas performed.
(E and F) HLA-negative and HLA-B*3501-expressing target cells were infected with either Gag-260E or Gag-260D virus and tested for epitope recognition by
specific CD8T cells determined by IFN- production after coculture and shown forGag-NY10 epitope processing (left) or the control Pol-EY10 epitope (right)
by fluorescence-activated cell sorter (FACS) plots (E) and shown as horizontal bar graphs (F). Peptide-pulsed target cells (PEP)were included as a positive control
for optimal epitope presentation.
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ant can make an NY10-260D-specific response, from which the
viral escape mutant D260E is selected.
To test this hypothesis, i.e., that NY10 responses in B-clade-
infected subjects are either cross-reactive between the two NY10-
260D andNY10-260E variants or specific to the NY10-260D form
but are never specific for the NY10-260E variant, we generated
HLA-B*3501-NY10-260D and HLA-B*3501-NY10-260E tetram-
ers with which to stain NY10-specific CD8 T cells. Staining of
PBMCs and antigen-specific cell lines with these two HLA-
B*3501-NY10 tetramers was consistent with the hypothesis (Fig.
5C andD). In vitro expansion ofNY10-specificCD8T cells in the
rare B-clade-infected persons showing a response to this epitope
showed, irrespective of which variant had been used to stimulate
PBMCs, preferential recognition of the NY10-260D (C-clade ver-
sion) of the epitope (Fig. 5B). Where there is apparent cross-reac-
tion of NY10-260D-specific CD8 T cells to the NY10-260E vari-
ant (Fig. 5C), following in vitro expansion of these cells using
either theNY10-260Dor theNY10-260E peptide, preferential rec-
ognition of the NY10-260D epitope consistently emerges. Dual
NY10-260D and NY10-260E tetramer staining confirms that only
cross-reactive or NY10-260D-specific CD8 T cells exist, with no
detection of NY10-260E-specific CD8 T cells (Fig. 5D). To test
whether the 260E escape version has a reduced recognition com-
pared to the 260D version using intracellular processed epitopes,
rather than peptide-pulsed cells, we infected HLA-B*3501-posi-
tive or HLA class I-negative cells with HIV containing either the
260D or the 260E virus and determined the level of NY10 epitope
recognition by assaying the activation of an NY10-specific CD8
T-cell line after coculture with cells infected for 6 days (Fig. 5E and
F). We detected almost 3-fold-higher activation after infection
with the 260D virus compared to the 260E virus (CD8/IFN-,
60.6% versus 23.3%) but equal activation of the control Pol EY10-
specific CD8 T-cell clone. Thus, infection with the 260E virus
results in a markedly reduced recognition of the nonimmuno-
genic NY10-260E compared to the immunogenic NY10-260D
epitope processed from the 260D virus.
NY10-260E nonimmunogenicity results from lack of HLA-
B*3501–peptide binding affinity and stability. Given that the
peptide-binding motif for HLA-B*3501 does not show any pref-
erence for particular residues at position 8 (P8) in the epitope, our
initial hypothesis was that nonimmunogenicity of the NY10-260E
variant might be related to the low TcR repertoire available for
HLA-B*3501-restricted T-cell responses, as proposed by Kosmrlj
et al. (41). However, to determine whether that NY10-260E non-
immunogenicity might be more readily explained as a result of
weak HLA-B*3501 binding affinity and/or stability, we first per-
formed these MHC binding studies. We found that the immuno-
genic, NY10-260D (C-clade) version of the peptide had a 10-
fold-greater binding affinity to the HLA-B*3501 molecule than
the NY10-260E (B-clade) variant and was more than three times
more stable in complex with the HLA-B*3501 molecule than the
NY10-260E version (half-life, 1.6 h versus 0.5 h) (Fig. 6A). Previ-
ous studies suggest that, with rare exceptions, a peptide-MHC
stability half-life of 1 h is required for peptides to be immuno-
genic (31). The low peptide-MHC binding stability of the NY10-
260E variant (half life, 0.5 h) would therefore explain the lack of
NY10-specific responses observed for the B-clade cohorts studied
here. This is also consistentwith reduced recognition of theNY10-
260E versus theNY10-260Dversion of the epitope shown in Fig. 5.
It is noteworthy that had PY9 as opposed to NY10 been the
optimal epitope in this case, it would not have been able to explain
lack of immunogenicity of the B-clade variant in this way. Both B-
and C-clade versions of PY9 had low peptide-binding affinities to
HLA-B*3501, in particular theGag-260D (C-clade) version (Kd
76 and 407 nM for PY9-260E and PY9-260D, respectively), and
very low peptide-B*3501 binding stabilities, again lower for the
FIG 6 Binding of NY10 Gag and PY9-Gag to the HLA-B*3501 molecule. Strength of binding affinity (Kd, nM) of HLA-B*3501 was determined using the
luminescent oxygen channeling immunoassay, as previously described (29) (top panels), and stability half-life (t1/2) of binding (h) was determined using
scintillation proximity assay, as previously described (30) (bottom panels), for NY10 (A) and PY9 (B). Results from one representative of four independent
experiments are shown.
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Gag-260DC-clade version of PY9 (half-life of 0.62 h and 0.34 h for
PY9-260E and PY9-260D, respectively).
Together these data suggest that the observed differentialHLA-
B*3501 association with HIV disease progression in B- and C-
clade infectionmay hinge on a single Gag epitope, NY10, and that
the lack of immunogenicity of this epitope in B-clade infection
rests on the presence of Glu at Gag-260 in the consensus B-clade
sequence, in contrast to Asp at Gag-260 in the consensus C-clade
sequence.
DISCUSSION
The data presented here demonstrate that subjects with HLA-
B*3501 control HIV-1 more effectively in C-clade than in B-clade
infection. This difference was associated with greater targeting of
p24 Gag epitopes and less frequent targeting of Env epitopes over-
all. However, the single epitope significantly targeted differentially
was the Gag NY10 epitope, targeted by 38% of HLA-B*3501-pos-
itive subjects with chronic C-clade infection and only 5% ofHLA-
B*3501-positive subjects with chronic B-clade infection. The rea-
son for this difference is the replacement of Asp byGlu atGag-260,
position 8within theNY10 epitope: inC-clade infection,75%of
sequences carry Asp at Gag-260, whereas in B-clade infection,
90% of sequences carry Glu at Gag-260. NY10-260E is nonim-
munogenic and insufficiently recognized from infected cells
(25% CD8 T-cell activation) because this variant fails to bind
sufficiently stably to HLA-B*3501. In contrast, the NY10-260D
version is recognizedmore efficiently (60%CD8 T-cell activa-
tion) and binds relatively stably to HLA-B*3501 (off-rate half-life
of 1.6 h, compared to 0.5 h for NY10-260E). The binding affinity
of HLA-B*3501 for NY10-260Dwas also substantially higher than
that for NY10-260E (Kd of 10 nM versus 113 nM, respectively),
consistent with the difference in antigen processing of this
epitope. These findings provide a plausible explanation for why
NY10-260E is an escape variant in B- and C-clade infection and
why only the NY10-260D variant is immunogenic.
Several hypotheses have previously been proposed to ex-
plain the rapid disease progression of HLA-B*3501-positive
subjects infected with B-clade HIV, including a paucity of
HLA-B*3501-restricted Gag-specific CD8 T-cell epitopes
(39), failure to optimize antiviral NK activity (51, 52) and nar-
rowness of the TcR repertoire available to counter epitope se-
quence variability (41). The data presented here support the
“Gag hypothesis” (39), in that even the addition of a single
extra Gag response appears to significantly alter the impact of
HLA-B*3501 in HIV infection. This is consistent with previous
findings that increasing Gag-specific CD8 T-cell breadth is
correlated with increasing viral suppression (39) and that the
p24 Gag protein is infrequently targeted by HLA-B*3501-re-
stricted CD8 T-cell responses in B-clade infection (67). These
data also support previous studies that have suggested that
even one effective CTL response can mediate long-term im-
mune control of immunodeficiency virus infection, such as the
KK10 (Gag positions 263 to 272) response in HIV-infected
subjects with HLA-B*27 (27) or the SW9 (Gag positions 241 to
249) response in simian immunodeficiency virus (SIV)-in-
fected Burmese macaques expressing the MHC 90-120-Ia hap-
lotype (35, 70).
These data show that inadequate HLA-B*3501 binding of the
peptide, as opposed to TcR paucity, as has been proposed as a
mechanism for HLA-B*3501-associated rapid progression (41),
may provide the explanation for the lack of a response to NY10-
260E in B-clade infection. The two hypotheses are not mutually
exclusive, and it remains possible that HLA-B*3501 is associated
with some degree of protection against C-clade progression in
spite of TcR paucity. However, the distinction is of direct rele-
vance to vaccine design, since we show here that HLA-associated
disease outcome is dependent on the epitopes being targeted, ir-
respective of any deficiencies attributed to the respective HLA
molecule. Furthermore, it is striking that HLA-B*0702 and HLA-
B*3501, the two alleles proposed to predispose to rapid HIV pro-
gression as a result of TcR paucity (41), both have a more success-
ful impact on the viral set point in C-clade infection (Fig. 1), as do
many other alleles within the HLA-B7 supertype whose peptide-
binding motifs are very similar, namely, HLA-B*8101, B*4201,
B*0705, and B*3910 (45).
These studies also draw attention to caveats associated with
epitope prediction approaches using peptide-binding motifs or
even those using the most sophisticated software that takes ac-
count of the possible contribution to MHC binding of every
amino acid of every peptide known to bind to a particular MHC
class I molecule. Although PPIPVGDIY (PY9) has appeared in the
“A” list of HIV-specific CD8 T-cell epitopes since 1995 (48) and
epitope prediction programs predict that PY9 would bind better
than NY10 to HLA-B*3501 (17), nonetheless PY9 is not the
epitope. It is significant that 0/377 peptides eluted fromHLA class
I molecules and sequenced have Pro at P1 (44). Bearing in mind
the specificity of ERAP-1, which cleaves neither at X-P nor at P-X
bonds (32), it seems that epitopes carrying Pro at P1, if they exist at
all, are rare. The importance of defining the precise optimal
epitope correctly is underlined by this study, in the demonstration
that the 10-mer NY10 could only be immunogenic with Asp at P8
(Fig. 5). In contrast, although PY9-260E bound with stronger
avidity than PY9-260D to HLA-B*3501, neither version of the
9-mer PY9 appeared to bind HLA-B*3501 with adequate stability
to be immunogenic. It may be helpful in the future to confirm the
identification of novel epitopes using peptide-MHC I tetramers,
as now can be done readily (40, 43).
The critical contribution to MHC binding of the residue at P8
in an HLA-B*3501-restricted epitope was unexpected, given the
peptide-bindingmotif of HLA-B*3501, which describes proline at
P2 and Tyr at PC as the primary anchor residues, with various
residues less strongly preferred at P2, P3, P4, and PC (18, 33).
Explanation of this awaits the solution of the crystal structure of
the HLA-B*3501–NY10-260D complex. However, an HLA-
B*3501-EBV epitope structure has been solved (71), and model-
ing the HLA-B*3501-NY10 structure based on these data suggests
that Asp at P8 in the NY10 epitope indeed points into the groove
(Fig. 7). The model suggests that replacement of Asp by Glu at P8
would lead to steric hindrance between the longer side chain of
Glu and the side chain of Ala-150 in the MHC 2 helix. The re-
sulting altered conformation of the peptide would explain the
observed reduction in stability of NY10-260E (Fig. 6B). This is
consistent with the reduced but detectable processing of the
NY10-260E peptide (data not shown) and is directly explained by
the reduced affinity to the MHC molecule and thereby suggests
that the limiting step in processing of the NY10-260E peptide
occurs when the fully trimmed epitope is loaded onto the HLA-
B*3501 molecule by the peptide-loading complex. This reduction
in processing of the NY10-260E epitope may be critical to distin-
guish immunogenicity, especially at low infection levels of pri-
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mary CD4 T cells in vivo, in contrast to the highermultiplicity of
infection used in vitro in this assay.
The high frequency (75%) of the D260E selection in C-clade
infection suggests a highly functional Gag NY10-specific CD8
T-cell response in vivo. However, when we undertook sequencing
of the Gag NY10 region from position 253 to 262 of 17 HLA-
B*3501-positive recipients with known Gag NY10 sequences of
their linked donor viruses, we did not find any selection of D260E
escape mutation at very early viral load set points (CD4 count
nadir) in 10HLA-B*3501 individuals infectedwith the 260D virus
(0/10) (data not shown). This suggests that the D260E selection
occurs after the CD4 nadir during chronic infection and that the
Gag NY10 response therefore may operate during chronic infec-
tion rather than during acute infection. This is consistent with a
previous study showing that the HLA-B*3501-D260Emutation is
selected outside acute infection (54). Moreover, we did not ob-
serve any change in the viral load set point for individuals carrying
260D versus 260E within linked recipients (37,720 versus 39,740
RNA copies/ml plasma; P  0.6) early after infection or during
chronic infection (17,550 versus 26,600 RNA copies/ml plasma;
P 0.58) (data not shown). However, the small numbers in com-
bination with the potential compensatory mutations identified,
which may restore viral fitness, may mask differences in viral load
set point.
Although the residue at Gag-260 appears to play an important
part in immunogenicity of the HLA-B*35:01-NY10 epitope, it is
also important to note that, aswithmany amino acid substitutions
in p24 Gag, this single-amino-acid substitution at Gag-260 is of-
ten observed in association with a number of other variations
elsewhere in p24 Gag. In a covariation analysis (14), we identified
9 statistically significant associations (q  0.05) between Gag-
260D and variation at other positions (see Table S3 in the supple-
mental material), which may indicate that the D260E escape in
C-clade virus may require compensatory mutations to minimize
the impact on viral replicative capacity.
One further observation with respect to epitope definition
highlighted by this study is the value of using a panel of overlap-
ping peptides to comprehensively map responses made by HIV-
infected subjects, as opposed to using epitope prediction. The
other p24 Gag epitope defined here in HLA-B*3501-positive sub-
jects, HPVHAGPIA (HA9), may have gone unnoticed previously
becauseHLA-B*3501 typically shows a binding preference for Tyr
or a larger hydrophobic residue than Ala at the C terminus. Be-
tween 40 and 60% of subjects studied here with HLA-B*3501
made a response to HA9, and, like for the NY10 Gag response,
responders had significantly lower viral loads than nonre-
sponders. Thus, a critical epitope within p24 Gag would have re-
mained undetected had we used an approach based on predicted
epitopes only.
Of note, we unexpectedly showed that a response to one of the
Nef epitopes, NY8, was also associated with a lowered viremia in
both B- and C-clade infection. CD8 T-cell responses to Nef have
not typically been associated with disease control (39), but the
data presented here suggest that specific responses withinNefmay
also mediate viremic suppression. In a previous study, it was ob-
served that a substantial number of the Nef escape mutations re-
vert following transmission to an HLA-mismatched host (54),
suggesting a cost to viral fitness; the escape polymorphism itself
may therefore contribute to disease control via an effect on viral
replicative capacity. This finding is also consistent with data de-
scribing effective control of SIV in Mamu-B*08- and Mamu-
B*17-positive rhesus macaques, which tend to target dominant
epitopes not in Gag but in proteins such as Nef and Vif (49, 57).
Thus, although a broadGag-specificCD8T-cell responsemay be
more likely to be effective against HIV, it remains possible that
CD8 T-cell responses targeting epitopes in non-Gag proteins
may also be effective in containment of immunodeficiency virus
infection.
It is important also to consider the limitations of this study. In
particular, attention should be drawn to the fact that optimal
HLA-B*3501-restricted epitopes 8 to 11 amino acids in length
were tested for recognition in the B-clade-infected Japanese study
subjects, whereas theC-clade-infected subjects were tested for rec-
ognition of the 18-mer overlapping peptides containing those op-
timal epitopes. Although responses to the 18-mer and to the op-
timal epitope have been strongly correlated (16) (r  0.85; P 
0.0001 [H.N. Kloverpris et al., unpublished data]), themagnitude
of response to the 18-mer tends to be somewhat lower than that to
the optimal epitope, particularly if the location of the optimal
epitope is in the central part of the 18-mer peptide (16, 55). How-
ever, this likely underestimation of the responses in the C-clade-
infected study subjects, where response frequencies were deter-
mined using the 18-mer overlapping peptides, would likely have
reduced the estimates of the frequency ofGagNY10 responses and
of Gag HA9 responses, detected in 38% and 52% of subjects, re-
spectively. Therefore, the difference in targeting of p24 Gag
epitopes that exists between B- and C-clade-infected subjects is
likely, if anything, to be even greater than shown in Fig. 4.
In summary, the impact ofHLA alleles such asHLA-B*3501 on
HIVdisease outcome differs according to clade of infection. These
data suggest that the critical difference in C-clade infection is the
ability of HLA-B*3501-positive subjects to make two p24 Gag-
specific responses restricted by this allele, NY10 and HA9, com-
pared to only one (HA9) in B-clade-infected subjects. This result
provides the clearest data yet that HLA-associated disease out-
come is dependent on the epitopes being targeted, irrespective of
FIG 7 Modeled B3501-NY10 structure using the B3501-EPLPQGQLTAY
complex (71). (A) HLA-B*3501 (shown in gray cartoon)-NPPIPVGDIY
(shown in blue sticks), looking down at the MHC-binding groove. Position
P8D in the peptide is circled. (B) HLA-B*3501 (shown in gray cartoon)-NPP
IPVGEIY (shown in red sticks), looking down at the MHC-binding groove.
P8E is circled. (C) Modeled interaction with NY10 residue P8D (blue stick)
and MHC residues A150 and V152 (green sticks). (D) Modeled interaction
with NY10 residue P8E (red stick) and MHC residues A150 and V152 (green
sticks). The longer side chain of E in the escape mutant NY10 compared to D
in the wild-type NY10 could generate steric hindrance with MHC residue
A150. This could destabilize, and change the conformation of, theNY10 escape
mutant peptide.
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the nature of the restricting HLAmolecule (55), and this provides
hope that a vaccine that can induce effective CD8 T-cell re-
sponses can successfully bring about immune control even in peo-
ple who carryHLA alleles traditionally regarded as associated with
rapid disease progression.
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